Navigation Links
Avalon Pharmaceuticals to Present at the American Association for,Cancer Research 2007 Annual Meeting

GERMANTOWN, Md., April 10, 2007 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. , today announced that AVN944 will be the subject of three poster presentations at the American Association for Cancer Research 2007 Annual Meeting to be held on April 14-18, 2007 in Los Angeles, Calif.

The first poster presented by Avalon, will review the data derived from the Avalon ongoing Phase I clinical trial of AVN944 for the treatment of hematological cancers. The poster is titled, "The Modulation of Gene Expression and Guanosine Pools by Inhibition of Inosine Monophosphate Dehydrogenase (IMPDH); correlating In Vitro Cell Resistance with Biomarker Response in Patient Samples from the Phase I Trial." This poster will provide data from clinical samples that correlate IMPDH inhibition, GTP pool suppression, and associated changes in tumor cell gene expression. The presentation will be Monday, April 16, 2007 from 8 a.m. until noon Pacific Time.

The second Avalon poster presentation is titled, "Antiangiogenic Properties of AVN944, A Potent Inhibitor of IMPDH." The poster will describe in vitro and in vivo experiments that reveal the effects of AVN944 on blood vessel formation. The presentation will be on Tuesday, April 17, 2007 from 8 a.m. until noon Pacific Time.

Another poster that will discuss AVN944 will be presented by the lab of Dr. Beverly Mitchell of Stanford University. The poster is titled, "GTP depletion induces translocation of TIF-IA and PAF53, inhibition of pre-rRNA synthesis and dislocation of nucleolar proteins." The presentation cites AVN944 as a compound that has effects on rRNA inhibition and nucleolar protein translocation. The poster presentation will be Tuesday, April 17, 2007 from 1 p.m. until 5 p.m. Pacific Time.

All three posters are in the Experimental and Molecular Therapeutics Poster Sessions.

AVN944 is an oral small molecule drug candidate that inhibits inosin
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
2. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:11/28/2008)... Germany, November 28 German biote...hip in specialized HIV monitoring and,AIDS patien...g countries. In,the year 2008, 2.5 million patien...bust and highly affordable "CyFlow" system, suppor...th HIV/AIDS. Due to introduction of the,Partec in...
(Date:11/26/2008)...nn., Nov. 26 Children w...significantly increased risk of developing mental ...of a Mayo Clinic study published this month in Pe...ademy of Pediatrics. , , The retrospective ... with strabismus (misaligned eyes) and compared th...
(Date:11/25/2008)...ness can improve recovery , , Audio and Web...able on the Mayo Clinic News Blog. Please see the ... ROCHESTER, Minn., Nov. 25 /PRNewswire-USNewswire...e patients don,t think they,re having a stroke -- ...heir condition worsens. The findings appear in the...
(Date:11/25/2008)...NCISCO, Calif., Nov. 25 Proteolix,...of novel therapeutics that target,protein degrada...oday,announced that data from two ongoing Phase 2...ma will be presented at the upcoming 50th Annual M...). Carfilzomib is the first in a new class,of sp...
Breaking Medicine Technology:German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Eye Divergence in Children Triples Risk of Mental Illness 2Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Homeland Security awards 2 grants to Rutgers for nuclear threat detection 422 1Homeland Security awards 2 grants to Rutgers for nuclear threat detection 422 2Homeland Security awards 2 grants to Rutgers for nuclear threat detection 422 3Fund Manager Joins Board of GSI Securitization Inc 1368 1Fund Manager Joins Board of GSI Securitization Inc 1368 2Billians HealthDATA GM Speaking on Dreamforce 07 Panel 1363 1Billians HealthDATA GM Speaking on Dreamforce 07 Panel 1363 2CryoLife Signs Distribution Agreement for Inclusion of BioGlue 28R 29 Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 614 1CryoLife Signs Distribution Agreement for Inclusion of BioGlue 28R 29 Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 614 2CryoLife Signs Distribution Agreement for Inclusion of BioGlue 28R 29 Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 614 3
...g therapeutic cancer vaccine,trials have yet to sh... immune system to shrink tumors -- yet patients wh...nger and respond,better to subsequent treatment. I...journal of the American Association for Cancer,Res...hers asks a,fundamental question: are we looking a...
...)--Jul 5, 2007 - Australian,biotechnology company ...apricitabine,s controlled, double blinded phase wh...ase IIb trial.,Patients have now progressed into t...) and will continue to receive 800mg,apricitabine ...e.,The Company expects to release results from the...
Other Medicine Technology:From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 2From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 3Avexa's Apricitabine Clinical Trial Update 2
(Date:12/2/2008)... NDA with FDA in Early to Mid-2009 , , WARR...velopers of PharmFilm(R) technology and a drug del... pharmaceutical products, and Strativa Pharmaceuti...rmaceutical Companies, Inc. (NYSE: PRX ), today ... bioequivalence studies for a thin film formulatio...
(Date:12/2/2008)...c. 2 With the bright lights, sweet...holidays may be an exciting time of year for any c..., especially with today,s tough economy. Whether ...ptying their wallets, or spending hours traveling ...elax, and even less time to be alone and romantic ...
(Date:12/2/2008)...Dec. 2 Aduromed Industri...ovider of medical waste treatment,systems, today ... on November,24, 2008 to protect the Company,s pr...nerized MedClean Systems that provide a turnkey so...zation and volume reduction. , The patent a...
(Date:12/2/2008).... 2 Mylan Inc. (NYSE: ... Mylan Pharmaceuticals Inc., have entered,into a ... Corp., Novartis,Corp. and Novartis International...sion of Novartis, Femara(R). , Mylan,s Vice...re very,pleased to have reached this agreement, w...
Breaking Medicine News(10 mins):Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 3Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 2Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 3Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 2Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2
... the risk of diabetes in the Indigenous population...ott, Pro-vice Chancellor of the Division of Health...ows that while clinical care of adults with diabet...ndigenous Australians are developing the disease. ...
... epidemic of diabetes in the US is out. Spending o.... According to a drug trend report released by th...ailed only cholesterol medications in total prescr...n 2006. An aging population and the alarming rise...
...disfiguring accident that nearly killed him, but h...s home on Andrews Air Force Base in Maryland. N...e, that is, because of his brand-new nose. In a s... over a year-long period that ended with removal o...
...al Boston) and colleagues have identified the canc... soft-tissue sarcoma of childhood. 'Identifying ...ved genetic programs underlying self-renewal in ER... into how to destroy these cell types in establish...
Other Medicine News:Health News:Spending on Diabetes Drugs Soars in US 2Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 2Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 3Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 4Health News:Pediatric Cancer Stem Cell Identified 2
Bard Coude-Tip Latex Urethral Catheter, Two Eyes (Tiemann Model)
Used for stone manipulation and removal in the urinary tract. Supplied sterile in peel-open packages. Intended for one-time use.
The Coude tip design facilitates negotiation of the prostatic urethra. It is available in a medium length olive Coude tip with a single drainage eye. The red latex construction provides added stiffne
BARDEX Red Rubber Urethral Catheter (Robinson Model)
Medicine Products: